• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Introduction to 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1934501-61-7)

5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1934501-61-7) is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its unique structural features and potential biological activities. This compound belongs to the pyrrolopyridine class, a scaffold that is widely recognized for its role in the development of various therapeutic agents. The presence of both bromine and propyl substituents in its molecular structure enhances its utility as a key intermediate in synthetic chemistry, enabling further derivatization for drug discovery purposes.

The bromine atom at the 5-position and the propyl group at the 3-position of the pyrrolopyridine core contribute to the compound's reactivity and versatility. These substituents allow for selective functionalization, making 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine a valuable building block in organic synthesis. Recent advancements in medicinal chemistry have highlighted the importance of such heterocyclic compounds in designing molecules with enhanced pharmacological properties.

In recent years, there has been a surge in research focused on developing novel therapeutic agents derived from pyrrolopyridine derivatives. These compounds have shown promise in various preclinical studies, particularly in the areas of oncology, immunology, and central nervous system disorders. The structural motif of 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine is particularly intriguing because it combines the bioisosteric properties of pyrrole and pyridine rings, which are known to interact favorably with biological targets.

One of the most compelling aspects of 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine is its potential as a scaffold for drug development. The bromine atom serves as an excellent handle for cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are pivotal in constructing complex molecular architectures. Additionally, the propyl group can be further modified through various chemical transformations, including alkylation, oxidation, or reduction, to tailor the compound's pharmacokinetic and pharmacodynamic profiles.

Recent studies have demonstrated the efficacy of 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine derivatives in modulating key biological pathways. For instance, certain analogs have been found to exhibit inhibitory activity against enzymes involved in cancer cell proliferation and survival. The brominated pyrrolopyridine core has also shown potential in targeting immune checkpoint receptors, which are critical for developing immunotherapeutic strategies. These findings underscore the compound's significance as a lead molecule in drug discovery initiatives.

The synthesis of 5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine involves multi-step organic transformations that highlight its synthetic accessibility. The starting materials for this synthesis can be readily obtained from commercial sources or prepared through established synthetic routes. The bromination step at the 5-position is particularly well-documented and can be performed using standard brominating agents under controlled conditions. Similarly, the introduction of the propyl group at the 3-position can be achieved through nucleophilic alkylation or other suitable methods.

In conclusion,5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1934501-61-7) represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features and synthetic tractability make it an attractive scaffold for developing novel therapeutic agents. As ongoing studies continue to uncover new biological activities associated with pyrrolopyridine derivatives,5-Bromo-3-propyl-1H-pyrrolo[2,3-b]pyridine is poised to play a significant role in future drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)